Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis
| Autor: | Toshio Morizane, Atsushi Yoshida, Yutaka Endo, Toshifumi Hibi, Fumiaki Ueno, Katsuyoshi Matsuoka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
RC799-869 Inflammatory bowel disease Gastroenterology inflammatory bowel disease Internal medicine adalimumab medicine Clinical endpoint Adalimumab cardiovascular diseases golimumab business.industry Retrospective cohort study Odds ratio primary failure Diseases of the digestive system. Gastroenterology medicine.disease Ulcerative colitis Infliximab Golimumab business infliximab medicine.drug Research Article |
| Zdroj: | Inflamm Intest Dis Inflammatory Intestinal Diseases, Vol 6, Iss 2, Pp 117-122 (2021) |
| Popis: | Background: Anti-tumor necrosis factor-α (TNF-α) agents are effective for moderately to severely active ulcerative colitis (UC). Nonetheless, a proportion of patients fail to respond to these agents as therapy for induction of remission. Recent studies indicated that perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) may predict response to anti-TNF-α agents in UC patients. However, whether PR3-ANCA can predict primary nonresponse (PNR) to anti-TNF-α agents has not yet been evaluated. The aim of this study was to examine whether PR3-ANCA can predict PNR to anti-TNF-α in UC patients. Methods: This was a single-center retrospective study. Data were extracted from 50 patients with UC who had measurements of PR3-ANCA and received anti-TNF-α agents for the first time as induction therapy. The primary endpoint of this study was a proportion of patients with PNR stratified by PR3-ANCA positivity. PNR to anti-TNF-α agents was defined as failure to achieve reduction in partial Mayo score by 2 or more points and change to other therapeutics within 6 weeks. Results: Fourteen (28%) of the 50 patients were PR3-ANCA positive. Seventeen (34%) of the 50 patients demonstrated PNR. Eleven (78.6%) of the 14 PR3-ANCA-positive patients demonstrated PNR, while 6 (16.7%) of the 36 PR3-ANCA-negative patients demonstrated PNR. Multivariate analysis demonstrated that PR3-ANCA positivity was associated with PNR to anti-TNF-α agents (odds ratio 19.29, 95% CI: 3.30–172.67; p = 0.002). Conclusion: PR3-ANCA positivity can predict PNR to anti-TNF-α agents in UC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|